Methenamine

Summary

Methenamine (CHEMBL1201270) is an approved small-molecule antibacterial drug (ATC J01XX05); indicated across 4 conditions including bacterial infectious disease and interstitial cystitis.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: J01XX05
• Indications: 4 conditions
• Clinical trials: 3
• Chemistry: 140.19 Da · C6H12N4

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1201270
Name	Methenamine
Type	Small molecule
Max phase	4
FDA approved	yes
PubChem CID	4101
ChEBI	CHEBI:6824
ATC	J01XX05
Molecular formula	C6H12N4
Molecular weight	140.19
InChIKey	VKYKSIONXSXAKP-UHFFFAOYSA-N

SMILES: C1N2CN3CN1CN(C2)C3

IUPAC name: 1,3,5,7-tetrazatricyclo[3.3.1.13,7]decane

ChEBI definition: A polycyclic cage that is adamantane in which the carbon atoms at positions 1, 3, 5 and 7 are replaced by nitrogen atoms.

Pharmacological roles (ChEBI): antibacterial drug.

Also known as: Aminoform, E-239, E239, Hexamethylene tetramine, Hexamine, INS NO.239, INS-239, Metenamina, Methenamine, NSC-26346, NSC-403347, Uritone

Parent form; salt/anhydrous children: CHEMBL1201104, CHEMBL3707448, CHEMBL3833312

Patent coverage: 41,644 distinct patent families (84,764 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

4 indications (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
bacterial infectious disease	4	MONDO:0005113	EFO:0000771
interstitial cystitis	3	MONDO:0018301	EFO:0008507
osteomyelitis	0	MONDO:0005246	EFO:0003102

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 3.

Phase distribution

Phase	Trials
PHASE3	2
PHASE4	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT03379389	PHASE4	COMPLETED	Clinical Assessment of Urinary Antiseptics Methenamine and Methylthioninium in Recurrent Cystitis
NCT01657448	PHASE3	COMPLETED	Efficacy Study of Methenamine + Methylthioninium Chloride vs Phenazopyridine for the Symptomatic Control of Dysuria
NCT05658874	PHASE3	TERMINATED	A Multidisciplinary, Multimodal Bundled Care Approach to Chronic Pelvic Pain

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).